Details of the Drug Combination

General Information of Drug Combination (ID: DCCNH33)

Drug Combination Name
Paromomycin Sodium stibogluconate
Indication
Disease Entry Status REF
Visceral Leishmaniasis Phase 3 [1]
Component Drugs Paromomycin   DM1AGXN Sodium stibogluconate   DMH5MVE
Small molecular drug N.A.
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Paromomycin
Disease Entry ICD 11 Status REF
Amoebiasis 1A36 Approved [2]
Hepatic coma N.A. Approved [2]
Intestinal amebiasis 1A36 Approved [3]
Paromomycin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) TTQ8KVI F4NA87_STAAU Binder [7]
------------------------------------------------------------------------------------
Paromomycin Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Serine-protein kinase ATM (ATM) OTQVOHLT ATM_HUMAN Increases Expression [8]
------------------------------------------------------------------------------------
Indication(s) of Sodium stibogluconate
Disease Entry ICD 11 Status REF
Advanced cancer 2A00-2F9Z Approved [4]
Leishmaniasis 1F54 Approved [5]
Solid tumour/cancer 2A00-2F9Z Phase 2 [6]
Sodium stibogluconate Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Leishmania DNA topoisomerase I (Leishm TOP1) TTNJKC3 Q9NJG8_LEIDO Modulator [6]
------------------------------------------------------------------------------------
Sodium stibogluconate Interacts with 13 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Expression [9]
Interferon gamma (IFNG) OTXG9JM7 IFNG_HUMAN Decreases Expression [9]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Decreases Expression [9]
Erythropoietin (EPO) OTZ90CN4 EPO_HUMAN Decreases Expression [10]
Interleukin-4 (IL4) OTOXBWAU IL4_HUMAN Decreases Expression [9]
Integrin alpha-M (ITGAM) OTAG6HWU ITAM_HUMAN Increases Expression [11]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Expression [9]
Interferon gamma receptor 1 (IFNGR1) OTCTQBWW INGR1_HUMAN Increases Expression [12]
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) OT2D9DOV TNR1A_HUMAN Decreases Expression [13]
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) OTDS2EAR TNR1B_HUMAN Decreases Expression [13]
Interleukin-10 (IL10) OTIRFRXC IL10_HUMAN Decreases Expression [9]
Tyrosine-protein phosphatase non-receptor type 6 (PTPN6) OT33XNZM PTN6_HUMAN Decreases Activity [11]
B-cell lymphoma 6 protein (BCL6) OTQAWWO1 BCL6_HUMAN Decreases Expression [14]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 DOT(s)

References

1 ClinicalTrials.gov (NCT03129646) Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa
2 Paromomycin FDA Label
3 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 064171.
4 Perspectives of antimony compounds in oncology. Acta Pharmacol Sin. 2008 Aug;29(8):881-90.
5 Leishmaniasis in Norway. Tidsskr Nor Laegeforen. 2021 Feb 22;141(3).
6 Inhibition of Leishmania donovani promastigote DNA topoisomerase I and human monocyte DNA topoisomerases I and II by antimonial drugs and classical antitopoisomerase agents. J Parasitol. 2004 Oct;90(5):1155-62.
7 Aminoglycoside association pathways with the 30S ribosomal subunit. J Phys Chem B. 2009 May 21;113(20):7322-30.
8 Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15676-81. doi: 10.1073/pnas.0405155101. Epub 2004 Oct 21.
9 Evaluation of localized and systemic immune responses in cutaneous leishmaniasis caused by Leishmania tropica: interleukin-8, monocyte chemotactic protein-1 and nitric oxide are major regulatory factors. Immunology. 2010 Jun;130(2):193-201. doi: 10.1111/j.1365-2567.2009.03223.x. Epub 2010 Jan 22.
10 Serum erythropoietin concentration in anaemia of visceral leishmaniasis (kala-azar) before and during antimonial therapy. Br J Haematol. 1998 Mar;100(4):720-4. doi: 10.1046/j.1365-2141.1998.00624.x.
11 Effects of sodium stibogluconate on differentiation and proliferation of human myeloid leukemia cell lines in vitro. Leukemia. 2002 Nov;16(11):2285-91. doi: 10.1038/sj.leu.2402692.
12 Antileishmanial drugs cause up-regulation of interferon-gamma receptor 1, not only in the monocytes of visceral leishmaniasis cases but also in cultured THP1 cells. Ann Trop Med Parasitol. 2003 Apr;97(3):245-57. doi: 10.1179/000349803235001714.
13 Soluble receptors for tumor necrosis factor as markers of disease activity in visceral leishmaniasis. J Infect Dis. 1995 Feb;171(2):498-501. doi: 10.1093/infdis/171.2.498.
14 SHP-1 is directly activated by the aryl hydrocarbon receptor and regulates BCL-6 in the presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Toxicol Appl Pharmacol. 2016 Nov 1;310:41-50. doi: 10.1016/j.taap.2016.08.014. Epub 2016 Aug 18.